Condition: Relapsed Adult Acute Myeloid Leukemia · Primary Refractory Acute Myeloid Leukemia · High Risk Acute Myeloid Leukemia · Sponsor: Massachusetts General Hospital
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
This description comes directly from the study's public registry record.
Areej El-Jawahri, MD · 617-724-4000 · ael-jawahri@mgb.org
Upeka Samarakoon, PhD · ssamarakoon@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital (MGH) | Boston, Massachusetts, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Not Yet Recruiting |
| Fred Hutchinson Cancer Research Center (FHCRC) | Seattle, Washington, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06472128